VIDEO: Adding romidepsin to CHOP does not improve PFS in peripheral T-cell lymphoma
Click Here to Manage Email Alerts
The addition of romidepsin to CHOP did not improve PFS in patients with peripheral T-cell lymphoma, according to an analysis presented at ASH Annual Meeting and Exposition.
Further, there was no statistical difference in response rates and OS for romidepsin plus CHOP compared with CHOP.
“This would be considered a negative study and clearly can’t be recommended as a new standard of care,” Stefan K. Barta, MD, MS, MRCP, director of the T-Cell Lymphoma Program at Penn Medicine, told Healio in a video interview.
However, Barta, who was moderator for this oral abstract presented at ASH, was interested to see that some patients in the study had “a very durable response.”
“It may be that T-follicular helper phenotype subgroup may benefit from the romidepsin – so it appears that there is a subgroup of patients who may derive benefit – but it just wasn’t enough to make the study positive and certainly isn’t enough to make it a new standard of care,” he said. “It certainly is hypothesis-generating that there may be a subgroup of patients who might benefit from the addition of an [histone deacetylase (HDAC) inhibitor] to CHOP. What remains to be done is to identify which that subgroup is.”
Romidepsin plus CHOP was also significantly more toxic, but Barta said that another HDAC inhibitor with a better toxicity profile plus CHOP may still be “worthwhile” for future research.
“I wouldn’t necessarily give up on the HDAC inhibitors in combination with CHOP,” he said.
Collapse
Bachy E, et al. Abstract 39. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Click Here to Manage Email Alerts